Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genetic Load and Phenotype in Aggressive AMD (RPED Genetics)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sequenom, Inc.
ClinicalTrials.gov Identifier:
NCT01650948
First received: July 24, 2012
Last updated: January 16, 2014
Last verified: January 2014

July 24, 2012
January 16, 2014
July 2012
December 2013   (final data collection date for primary outcome measure)
The identification of individual genetic markers or a quantitative measure of total genetic burden found to be significantly associated (p value <0.05) with group classification (CNV only versus CNV with GA and/or RPED). [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01650948 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Load and Phenotype in Aggressive AMD
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.

Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).

This study seeks to test individuals who have already progressed to various forms of AMD to evaluate correlations between genetic markers and particular features of AMD including geographic atrophy and pigment epithelial detachments. We hypothesize that patients with more aggressive forms of AMD will have a higher genetic burden contributed by markers in ARMS 2, Complement Factor H (CFH), Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), or other genetic polymorphisms associated with CNV.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

DNA samples and remnants will be destroyed after analysis.

Probability Sample

Patients with AMD who are or have been treated with anti-VEGF therapy

Age-related Macular Degeneration
Device: RetnaGene AMD LDT
  • AMD subjects with GA and/or RPED
    All subjects will have AMD and GA and/or RPED.
    Intervention: Device: RetnaGene AMD LDT
  • AMD subjects with CNV alone
    All subjects will have the CNV form of AMD only.
    Intervention: Device: RetnaGene AMD LDT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is male or female 50 years of age and older
  • Subject provides a signed and dated informed consent
  • Subject agrees to provide two buccal swabs in accordance with this protocol
  • Diagnosis of CNV secondary to AMD in at least one eye

Exclusion Criteria:

  • Previous sample donation under this protocol
  • Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD loss such as high myopia, retinal dystrophies, central serous retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 50.
  • Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate imaging of the posterior segment.
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01650948
SQNM-AMD-106
No
Sequenom, Inc.
Sequenom, Inc.
Not Provided
Not Provided
Sequenom, Inc.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP